MedTrace Logo

Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA)

NCT02094326 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 301

Last updated 2016-03-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find patterns in the use of non-biological DMARDs as the initial treatment of RA and how adverse events (AEs), intolerance or lack of efficacy may impact therapeutic decisions in real life in the Spanish Andalusian region.

Conditions

Sponsors & Collaborators

  • Fundación Andaluza de Reumatología

    lead OTHER

Principal Investigators

  • Federico Navarro, Dr. · Fundacion Andaluza de Reumatologia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02094326 on ClinicalTrials.gov